EGFR and non-small cell lung carcinoma: Clinical trials have demonstrated the efficacy of osimertinib against brain metastases in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have experienced disease progression with first- and second-generation EGFR-TKIs [4,5].